The research process
In 2016, the Foundation’s researchers measured vaccine company behaviour using a rigorous process of data-collection, verification, scoring and analysis in preparation for publishing the 2017 Access to Vaccines Index. Find out more about what this process involves.
Data-collection and verification
During data-collection, the research team used public sources of information as well as data submitted directly by the companies evaluated. During this phase, the research team followed a detailed process for verifying and clarifying the data it analyses. This includes requesting specific supporting documentation from companies as proof that the strategies and policies they report are being implemented in practice, including the codes of conduct, internal policies and processes for engaging with local stakeholders. The team also used public registries of information to cross-check certain data sets. Information about partnerships is also verified using information in the public domain, often published by product development partnerships.
Scoring the companies
The research team scored the companies in each of the Index metrics against a strict set of scoring guidelines, developed with reference to external experts. The research team compiled an extensive, detailed database of all products and R&D projects that qualify for analysis by the Index, for use as a central analytical platform.
Trend and gap analysis
Following scoring, the team combed through the data to assess the current level of activity across the industry to improve access to vaccines. Once analysis was complete, key sections of the report were shared with independent experts for their view on the findings.
The 2017 Access to Vaccines Index provides an initial baseline of company activity to improve immunisation coverage, which is a critical first step for stimulating change and increasing accountability. It highlights good practices, and areas where action is still required. Companies and other stakeholders can use this information to inform priorities and strategies, and to learn where new incentives or stronger mechanisms would spur companies towards greater engagement in access to vaccines issues.